MarginsXMarginsX
Home › Markets › Health Care › MRK

Merck & Company Inc. Common Stock (new) (MRK)

MRK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$144.46
-2.23% on the day
Market cap
$356.1B
Mega cap
Revenue · 2025
$65.0B
+1.3% on 2024
Net income · 2025
$18.3B
28.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/0000310158-26-000063-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMRK on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000310158
SEC industry codePharmaceutical Preparations
Incorporated inNJ

Financials · 2025

LineValue
Revenue$65.0B
Net income$18.3B
Operating incomeNot in SEC XBRL data
Net margin28.1%
Operating marginOperating income not reported
Revenue growth+1.3%
Cash$14.6B
Total assets$136.9B
P/E (computed)19.5×
P/S (computed)5.5×

Warning signs

Cash runway
Cash-flow positive
$9.6B cash at September 30, 2026
Share count, 1 year
-0.7%
2025-10-31 to 2026-10-31 · -2.7% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$72.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$9.6B cash; operating cash flow $4.7B a quarter.Report 2026-09-30
Shares outstanding2,465,245,688 (2026-10-31); 2,482,022,536 a year earlier; 2,534,023,084 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 4 424B5 takedownsLatest 2026-05-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-10-15
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $72.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18.1B$5.1B$6.6B$9.6B$53.8B$67.4B10-Q 2026-11-04
Q2 2026
2026-06-30
$16.6B-$1.3B$5.4B$6.8B$53.9B$66.6B10-Q 2026-08-07
Q1 2026
2026-03-31
$16.3B-$4.2B$3.9B$5.3B$49.1B$65.8B10-Q 2026-05-04
Q4 2025
2025-12-31
$16.4B$3.0B$2.9B$14.6B$49.0B$65.0B10-K 2026-02-24
Q3 2025
2025-09-30
$17.3B$5.8B$7.8B$18.2B$41.4B$64.2B10-Q 2026-11-04
Q2 2025
2025-06-30
$15.8B$4.4B$3.3B$8.0B$35.4B$63.6B10-Q 2026-08-07
Q1 2025
2025-03-31
$15.5B$5.1B$2.5B$8.6B$34.8B$63.9B10-Q 2026-05-04
Q4 2024
2024-12-31
$15.6B$3.7B$3.5B$13.2B$37.0B$64.2B10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-20
Latest annual report
10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025
10-K2026-02-24
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-10-29
Latest proxyDEFA14A2026-04-08

Source: SEC EDGAR submissions feed, 1,010 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.7%
1 month+4.1%
3 months+9.0%
Year to date+40.4%
1 year+59.0%
From 52-week high-5.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NVSNovartis AG$160.20-0.19%$305.7B
AZNAstraZeneca PLC$184.02-0.23%$285.4B
ABBVAbbVie Inc.$294.55-0.16%$520.7B
JNJJohnson & Johnson$282.55-1.12%$680.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
PFEPfizer Inc.$28.86-0.10%$164.5B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier